Technical Analysis for MNOV - MediciNova, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Gapped Up | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Stochastic Reached Overbought | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| MACD Bullish Centerline Cross | Bullish | 0.70% |
| Alert | Time |
|---|---|
| Down 2 % | about 8 hours ago |
| Down 1% | about 8 hours ago |
| 60 Minute Opening Range Breakdown | about 9 hours ago |
| Rose Above Previous Day's High | about 10 hours ago |
| Up 2% | about 10 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 08/08/2024
MediciNova, Inc. Description
MediciNova, Inc., a development stage biopharmaceutical company, focuses on acquiring and developing small molecule therapeutics for the treatment of serious diseases for the United States market. The company's principal product candidates include MN-166, an ibudilast-based drug candidate, which is in Phase I and Phase II clinical trials for the treatment of drug dependence and pain; and MN-221, a ß2 -adrenergic receptor agonist that has completed Phase II clinical trials for the treatment of acute exacerbations of asthma. It also has other product candidates in the clinical development for the treatment of acute exacerbations of asthma, multiple sclerosis and other central nervous system disorders, bronchial asthma, interstitial cystitis, solid tumor cancers, generalized anxiety disorders/insomnia, preterm labor, urinary incontinence, and thrombotic disorders. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pain Clinical Development Medication Central Nervous System Disorders Asthma Multiple Sclerosis Respiratory Therapy Nervous System Disorders Solid Tumor Cancers Insomnia Molecule Therapeutics Pulmonology Urinary Incontinence Bronchial Asthma Interstitial Cystitis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.66 |
| 52 Week Low | 1.26 |
| Average Volume | 25,255 |
| 200-Day Moving Average | 1.58 |
| 50-Day Moving Average | 1.37 |
| 20-Day Moving Average | 1.38 |
| 10-Day Moving Average | 1.39 |
| Average True Range | 0.07 |
| RSI (14) | 58.51 |
| ADX | 18.06 |
| +DI | 20.27 |
| -DI | 11.42 |
| Chandelier Exit (Long, 3 ATRs) | 1.27 |
| Chandelier Exit (Short, 3 ATRs) | 1.48 |
| Upper Bollinger Bands | 1.48 |
| Lower Bollinger Band | 1.28 |
| Percent B (%b) | 0.8 |
| BandWidth | 14.32 |
| MACD Line | 0.01 |
| MACD Signal Line | 0.00 |
| MACD Histogram | 0.0128 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.53 | ||||
| Resistance 3 (R3) | 1.53 | 1.50 | 1.52 | ||
| Resistance 2 (R2) | 1.50 | 1.48 | 1.50 | 1.51 | |
| Resistance 1 (R1) | 1.47 | 1.46 | 1.46 | 1.47 | 1.51 |
| Pivot Point | 1.44 | 1.44 | 1.43 | 1.44 | 1.44 |
| Support 1 (S1) | 1.41 | 1.42 | 1.39 | 1.41 | 1.37 |
| Support 2 (S2) | 1.38 | 1.40 | 1.38 | 1.37 | |
| Support 3 (S3) | 1.35 | 1.38 | 1.36 | ||
| Support 4 (S4) | 1.35 |
